BioLineRx to Present at Biotech Showcase 2016 Conference in San Francisco

News provided by

Jan 04, 2016, 07:00 ET

TEL AVIV, Israel, January 4, 2016 /PRNewswire/ --

BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the Biotech Showcase 2016 Conference being held in San Francisco, CA.

The BioLineRx presentation is scheduled to start at 10:00 a.m. PST (1:00 p.m. EST) on Monday, January 11, 2016. A live audio webcast of the presentation will be available online at BioLineRx's investor web page. An archive of the event will also be available for those unable to listen live. Company management will be available to participate in one-on-one meetings with investors who are registered to attend the conference. Meetings may also be scheduled outside of Biotech Showcase by contacting BioLineRx's investor relations.

About BioLineRx

BioLineRx is a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's leading therapeutic candidates are: BL-8040, a cancer therapy platform, which is in the midst of a Phase 2 study for relapsed/refractory AML, has recently initiated a Phase 2b study as an AML consolidation treatment, has recently initiated a Phase 1/2 study in hMDS and AA, and has successfully completed a Phase 1 study in stem cell mobilization; and BL-7010 for celiac disease, which has successfully completed a Phase 1/2 study. In addition, BioLineRx has a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates.

For more information on BioLineRx, please visit http://www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store.

Contacts for BioLineRx:
PCG Advisory
Vivian Cervantes
Investor Relations
+1-212-554-5482
[email protected]

or

Tsipi Haitovsky
Public Relations
+972-3-624-0871
[email protected]